Thrombosis and Hemostasis Biomarkers Market By Product & Test Type (Routine Coagulation Assays, D-dimer & Fibrinolysis Assays, Anti-Xa & Anticoagulant Monitoring Assays, Factor Activity & Bleeding Disorder Assays, Von Willebrand Factor Panels, Thrombophilia & Antiphospholipid Testing, Platelet Function Assays, Whole-Blood Viscoelastic Testing Systems); By Application (VTE Diagnosis & Exclusion, Sepsis & DIC Assessment, Bleeding Disorder Diagnosis, Anticoagulant & Treatment Monitoring, Trauma & Surgical Hemorrhage Management, Obstetric & Pregnancy-related Coagulation Disorders, Oncology-associated Thrombosis); By End User (Hospitals & Hospital-based Laboratories, Reference & Diagnostic Laboratories, Emergency & Critical Care Units, Specialty Hemostasis Centers, Outpatient Clinics & POC Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Thrombosis and Hemostasis Biomarkers Market: Acute Clot Exclusion, Specialty Coagulation, and Whole-Blood Testing Redirect Diagnostic Revenue

The Global Thrombosis and Hemostasis Biomarkers Market is projected to grow from USD 6.56 billion in 2025 to USD 10.96 billion by 2032, expanding at a CAGR of 7.6%, according to Strategic Market Research.

 

The thrombosis and hemostasis biomarkers market comprises laboratory assays, point-of-care systems, analyzers, reagents, test strips, cartridges, quality-control materials and specialist testing services. These products assess thrombosis, fibrinolysis, coagulation-factor activity, platelet function, anticoagulant effect and bleeding risk.

 

Completed tests, assay runs, cartridges, strips and laboratory reports are more useful measures of commercial demand than unique patient numbers. A patient evaluated for pulmonary embolism may undergo a D-dimer test followed by confirmatory imaging. Warfarin or unfractionated-heparin therapy may require repeated monitoring over months or years. Major bleeding episodes may generate PT/INR, aPTT, fibrinogen, platelet and viscoelastic results during the same hospital admission.

 

Relevant products span routine coagulation assays, D-dimer, anti-factor Xa, factor-activity assays, von Willebrand factor panels, thrombophilia tests and platelet-function assays. Whole-blood systems based on TEG, ROTEM or Quantra technology are also considered. General platelet counts are considered only when used in a dedicated DIC, bleeding or coagulation assessment.

 

Suspected VTE Creates a Testing Pool Larger Than Confirmed Cases

Venous thromboembolism supports the highest-volume acute pathway for D-dimer and related fibrinolysis assays. Up to 900,000 people are affected by VTE annually in the United States, while an estimated 60,000–100,000 Americans die from the condition each year. More than one-third of diagnosed cases are associated with a recent hospitalization, sustaining testing demand across emergency departments, postoperative follow-up, oncology units, and inpatient care.

A WHO patient-safety assessment estimated approximately 3.9 million annual VTE cases in high-income countries and 6 million in low-and middle-income countries. The combined estimate of nearly 9.9 million cases describes disease burden rather than assay utilization. Hospitals test a much larger population because many patients with chest pain, shortness of breath, limb swelling, or postoperative symptoms are ultimately found not to have DVT or pulmonary embolism.

Cancer creates a particularly testing-intensive subgroup. CDC estimates indicate that one in five blood clots is related to cancer or its treatment. Tumor type, disease stage, chemotherapy, hospitalization, surgery, central venous access, and mobility influence whether oncology patients receive D-dimer, platelet, fibrinogen, PT/aPTT, or broader coagulation testing. Testing volumes are therefore concentrated in high-risk oncology pathways rather than distributed evenly across the cancer population.

 

D-Dimer Testing Supports High Emergency-Care Demand

D-dimer is widely used to rule out deep vein thrombosis and pulmonary embolism in patients with a low or moderate risk of blood clots. A negative result can help hospitals avoid unnecessary imaging, making the test valuable in emergency departments and outpatient settings.

In an FDA-reviewed study, the INNOVANCE D-dimer assay showed 98.2% sensitivity and a 99.2% negative predictive value. However, positive results are less reliable because D-dimer levels can also rise due to age, pregnancy, infection, cancer, trauma, or surgery.

Hospitals therefore select D-dimer systems based on fast results, reliable cutoffs, analyzer compatibility, and clear reporting. Age-adjusted thresholds are also helping laboratories reduce false-positive results and unnecessary imaging in older patients.

 

Sepsis and DIC Generate Repeated Acute-Care Testing

At least 1.7 million U.S. adults develop sepsis annually, and at least 350,000 die during hospitalization or are discharged to hospice. Global estimates indicate 48.9 million sepsis cases and 11 million sepsis-related deaths. Only a subset develops suspected disseminated intravascular coagulation, but the volume of critically ill patients produces substantial demand for PT/INR, aPTT, fibrinogen, D-dimer, fibrin-degradation-product, and platelet testing.

DIC requires a combination of clinical findings and laboratory results rather than one positive biomarker. Laboratories assess platelet counts, PT prolongation, fibrin-related markers, fibrinogen, and serial changes. A critically ill patient may generate several coagulation panels over multiple days, particularly after transfusion, anticoagulant reversal, fibrinogen replacement, platelet administration, or changes in the underlying condition.

Laboratory assays, point-of-care systems, analyzers, reagents, test strips, cartridges, quality-control materials, and specialist testing services support evaluation of thrombosis, fibrinolysis, coagulation-factor activity, and platelet function within the thrombosis and hemostasis biomarkers market. Trauma, obstetric hemorrhage, liver failure, and complex cardiovascular surgery often require repeated testing. Rapid coagulation changes can outpace central-laboratory turnaround times, driving demand for whole-blood systems near operating rooms, intensive-care units, and trauma bays.

 

Bleeding-Disorder Diagnosis Supports Higher-Complexity Assays

Factor VIII, factor IX, inhibitor, VWF antigen, VWF activity, mixing, chromogenic, and genetic assays generate lower volumes than routine coagulation but require greater laboratory expertise and command higher testing value.

The World Federation of Hemophilia’s 2023 survey identified 218,804 people with hemophilia, 101,128 with von Willebrand disease, and 70,698 with other bleeding disorders across 119 reporting countries. The survey also recorded 6,368 hemophilia A patients and 326 hemophilia B patients with clinically identified inhibitors.

The 2024 WFH survey reported a 6% increase in identified hemophilia patients and a 6% increase in identified VWD patients. More than three-quarters of the expected global hemophilia population nevertheless remains unidentified or undiagnosed. Laboratories in underdiagnosed markets require factor assays, inhibitor testing, quality-control programs, trained personnel, referral networks, and access to specialist interpretation before biological prevalence can convert into routine testing revenue.

Von Willebrand disease illustrates the difference between estimated prevalence and diagnosed demand. Biological prevalence may reach 1% of the population, yet many affected individuals remain undiagnosed because symptoms are mild, inconsistent, or attributed to other causes. VWF concentrations can also increase during inflammation, pregnancy, stress, and trauma, leading clinicians to repeat testing under baseline conditions and interpret VWF antigen, platelet-dependent activity, factor VIII, and subtype results together.

Specialist centers and reference laboratories benefit from this complexity. Smaller hospitals often outsource multimer analysis, inhibitor confirmation, rare-factor testing, chromogenic assays, and genetic panels because annual specimen volumes do not justify maintaining every assay internally.

 

Whole-Blood Systems Convert High-Risk Procedures into Cartridge Demand

TEG, ROTEM, and Quantra systems measure clot initiation, clot stiffness, fibrinogen contribution, platelet contribution, and clot lysis from whole blood. Suppliers typically place instruments in hospitals and generate recurring revenue from cartridges, reagents, service contracts, software, and quality-control materials.

Trauma, liver transplantation, cardiac surgery, obstetric hemorrhage, and other high-acuity procedures account for most utilization. Hospitals adopt these systems when results are incorporated into transfusion and hemorrhage-management protocols, particularly where rapid decisions can reduce unnecessary plasma, platelet, cryoprecipitate, or fibrinogen use.

In August 2025, the FDA expanded the QStat Cartridge indication to include peripartum obstetric procedures alongside trauma and liver transplantation. The cartridge operates with the Quantra Hemostasis Analyzer and reports clot time, clot stiffness, fibrinogen contribution, platelet contribution, and clot stability to lysis. FDA documentation included 322 eligible obstetric subjects across seven U.S. clinical sites, with protocols permitting several specimens from one patient.

Procedure volumes cannot be converted directly into cartridge sales. Adoption varies by hospital, surgeon, anesthesiology team, and transfusion protocol, while one patient may generate baseline, intraoperative, and post-treatment results. Hospitals that embed viscoelastic testing into clinical algorithms create more predictable consumable demand than facilities using the systems only for occasional complex cases.

 

Routine Coagulation Assays Retain the Largest Product Share

Routine and specialty coagulation assays—including PT/INR, aPTT, fibrinogen, thrombin time, and anti-Xa—accounted for approximately 47.3% of market revenue in 2025. The segment is projected to expand at a 7.0% CAGR from 2026 to 2032.

Declining PT/INR utilization is being offset by high inpatient testing volumes, repeated heparin monitoring, expanding specialty coagulation menus, analyzer replacement, and recurring reagent contracts linked to installed systems. Whole-blood viscoelastic products are projected to record the fastest product CAGR at approximately 10.4%, supported by increasing use in trauma care, cardiac surgery, liver transplantation, and obstetric hemorrhage management.

 

VTE Assessment Leads the Application Mix

VTE diagnosis, exclusion, and broader coagulation assessment represented an estimated 43.6% of market revenue in 2025, according to the SMR model. The segment is forecast to grow at a 7.8% CAGR through 2032.

D-dimer use in emergency departments, cancer-associated thrombosis assessment, postoperative evaluation, and repeated DIC testing supports the segment’s leading position. Treatment monitoring remains commercially significant because anti-Xa, factor-recovery, inhibitor, and perioperative assays can generate multiple tests during one treatment course.

 

Hospital Laboratories Control Most Consumable Spending

Hospitals and hospital-based laboratories held an estimated 67.5% market share in 2025 and are projected to expand at a 7.7% CAGR from 2026 to 2032.

Emergency VTE assessment, intensive-care coagulopathy, heparin monitoring, trauma, cardiovascular surgery, transplantation, and obstetric bleeding keep most high-acuity testing within hospital networks. Reference laboratories capture rare-factor, VWF, inhibitor, genetic thrombophilia, and specialist confirmation assays that lower-volume hospitals cannot perform economically.

 

North America Leads While Asia-Pacific Expands Testing Capacity

North America accounted for an estimated 41.9% of global revenue in 2025 and is projected to grow at a 7.2% CAGR through 2032. Automated hospital laboratories, reimbursement for medically necessary testing, home and clinic INR monitoring, FDA-cleared viscoelastic systems, and established bleeding-disorder centers support regional revenue.

Asia-Pacific is forecast to record the fastest regional CAGR at approximately 9.3%. Hospital laboratory expansion, analyzer placements, specialist coagulation services, and improved identification of inherited bleeding disorders are increasing assay volumes across major urban healthcare systems.

 

Platform Footprint and Consumables Define Competitive Strength

Werfen, Siemens Healthineers, Diagnostica Stago, Sysmex, Roche Diagnostics, Haemonetics, HemoSonics, Quest Diagnostics, and Labcorp compete across different parts of the testing workflow. Analyzer placements, proprietary or validated reagents, service contracts, middleware, quality-control systems, and specialty assay menus provide stronger revenue protection than standalone biomarker ownership.

Werfen commercialized the ACL TOP Family 70 Series in North America in March 2025 following FDA clearance and Canadian licensure. Five configurations address laboratories ranging from lower-volume sites to highly automated hospital networks. HemoHub software centralizes quality control, performance verification, reporting, and instrument management, while automated checks identify hemolysis, icterus, lipemia, underfilled tubes, and clotted samples. Multi-hospital systems can use these functions to standardize results and reduce recollection across several sites.

Werfen also received FDA clearance in January 2025 for Aptiva antiphospholipid syndrome IgG and IgM reagents. The addition extends its presence from routine coagulation into autoimmune thrombosis assessment and creates cross-selling opportunities across hemostasis and autoimmunity laboratories.

Siemens Healthineers positions the CN-3000 and CN-6000 around consolidated routine and specialty testing. The CN-6000 can process up to 450 PT tests per hour, while both systems support automation connectivity and broad reagent menus. Large laboratories evaluate that capacity alongside staffing requirements, specialty-assay availability, reagent use, uptime, and compatibility with existing automation.

Roche retains a focused position in point-of-care and home INR monitoring through CoaguChek systems. Haemonetics competes through TEG instruments and cartridges, while HemoSonics targets rapid whole-blood assessment through the Quantra platform. Stago maintains a dedicated coagulation portfolio spanning routine and specialty testing, and Sysmex participates through analyzer systems and distribution partnerships.

Quest Diagnostics and Labcorp capture tests that require national scale, specialist interpretation, or low-volume assay menus. Rare-factor testing, VWF panels, thrombophilia panels, inhibitor assays, and genetic confirmation are particularly suited to reference laboratories because local hospitals may not receive enough specimens to operate these assays efficiently.

 

Specialty and Acute-Care Tests Will Capture More Revenue

D-dimer will remain a high-throughput emergency assay, although hospitals will favor platforms that reduce unnecessary positive results and connect assay interpretation with clinical pretest probability. Anti-Xa, VWF, factor-activity, inhibitor, antiphospholipid, and whole-blood assays generate higher-value revenue when results influence drug dosing, transfusion, procedural management, or specialist diagnosis.

Hospital laboratories are prioritizing platforms that combine routine and specialty menus, identify preanalytical errors, reduce recollection, connect multiple sites, and retain more specimens on one analyzer family. Whole-blood suppliers will gain utilization where cartridges become part of trauma, cardiac, transplant, and obstetric protocols rather than discretionary tests.

 

Thrombosis And Hemostasis Biomarkers Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 6.56 Billion
Revenue Forecast in 2032	USD 10.96 Billion
Overall Growth Rate	CAGR of 7.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product & Test Type, By Application, By End User, By Geography
By Product & Test Type	Routine Coagulation Assays, D-dimer & Fibrinolysis Assays, Anti-Xa & Anticoagulant Monitoring Assays, Factor Activity & Bleeding Disorder Assays, Von Willebrand Factor Panels, Thrombophilia & Antiphospholipid Testing, Platelet Function Assays, Whole-Blood Viscoelastic Testing Systems
By Application	VTE Diagnosis & Exclusion, Sepsis & DIC Assessment, Bleeding Disorder Diagnosis, Anticoagulant & Treatment Monitoring, Trauma & Surgical Hemorrhage Management, Obstetric & Pregnancy-related Coagulation Disorders, Oncology-associated Thrombosis
By End User	Hospitals & Hospital-based Laboratories, Reference & Diagnostic Laboratories, Emergency & Critical Care Units, Specialty Hemostasis Centers, Outpatient Clinics & POC Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	High testing volumes for acute VTE exclusion and D-dimer assessment Repeated coagulation monitoring in sepsis, DIC, anticoagulant therapy, trauma, and surgery Expanding demand for factor-activity, VWF, inhibitor, and antiphospholipid assays
Customization Option	Available upon request